After finishing at $8.90 in the prior trading day, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) closed at $9.43, up 5.96%. In other words, the price has increased by $+0.53 from its previous closing price. On the day, 2319522 shares were traded. AUPH stock price reached its highest trading level at $9.44 during the session, while it also had its lowest trading level at $8.95.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.10 and its Current Ratio is at 9.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 02 when MILNE GEORGE M JR bought 20,000 shares for $8.91 per share. The transaction valued at 178,284 led to the insider holds 70,000 shares of the business.
Greenleaf Peter sold 32,750 shares of AUPH for $292,785 on Mar 02. The Chief Executive Officer now owns 982,968 shares after completing the transaction at $8.94 per share. On Mar 02, another insider, Robertson Stephen P., who serves as the EVP, General Counsel of the company, sold 19,402 shares for $8.94 each. As a result, the insider received 173,454 and left with 303,364 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.88 while its Price-to-Book (P/B) ratio in mrq is 3.31.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $13.41, while it has fallen to a 52-week low of $4.07. The 50-Day Moving Average of the stock is 8.40, while the 200-Day Moving Average is calculated to be 8.00.
The stock has traded on average 3.20M shares per day over the past 3-months and 3.29M shares per day over the last 10 days, according to various share statistics. A total of 142.17M shares are outstanding, with a floating share count of 132.88M. Insiders hold about 0.10% of the company’s shares, while institutions hold 40.50% stake in the company. Shares short for AUPH as of Jan 30, 2023 were 11.03M with a Short Ratio of 14.96M, compared to 7.56M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.76% and a Short% of Float of 7.79%.
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.33, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.24 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.82 and -$0.91 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.88, with 7 analysts recommending between -$0.8 and -$0.99.
8 analysts predict $27.45M in revenue for the current quarter. It ranges from a high estimate of $30M to a low estimate of $25.4M. As of the current estimate, Aurinia Pharmaceuticals Inc.’s year-ago sales were $23.4M, an estimated increase of 17.30% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $26.13M, an increase of 20.80% over than the figure of $17.30% in the same quarter last year. There is a high estimate of $26.7M for the next quarter, whereas the lowest estimate is $25.3M.
A total of 8 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $136.4M, while the lowest revenue estimate was $131M, resulting in an average revenue estimate of $133.15M. In the same quarter a year ago, actual revenue was $45.6M, up 192.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $136.95M in the next fiscal year. The high estimate is $155.1M and the low estimate is $128.2M. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.